IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v31y2013i4p317-333.html
   My bibliography  Save this article

The Cost Effectiveness of Pharmacological Treatments for Generalized Anxiety Disorder

Author

Listed:
  • Ifigeneia Mavranezouli
  • Nick Meader
  • John Cape
  • Tim Kendall

Abstract

Sertraline appears to be the most cost-effective drug in the treatment of patients with GAD. However, this finding is based on limited evidence for sertraline (two published trials). Sertraline is not licensed for the treatment of GAD in the UK, but is commonly used by primary care practitioners for the treatment of depression and mixed depression and anxiety. Copyright Springer International Publishing Switzerland 2013

Suggested Citation

  • Ifigeneia Mavranezouli & Nick Meader & John Cape & Tim Kendall, 2013. "The Cost Effectiveness of Pharmacological Treatments for Generalized Anxiety Disorder," PharmacoEconomics, Springer, vol. 31(4), pages 317-333, April.
    • Handle: RePEc:spr:pharme:v:31:y:2013:i:4:p:317-333
    DOI: 10.1007/s40273-013-0031-z
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s40273-013-0031-z
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s40273-013-0031-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Brazier, John & Roberts, Jennifer & Deverill, Mark, 2002. "The estimation of a preference-based measure of health from the SF-36," Journal of Health Economics, Elsevier, vol. 21(2), pages 271-292, March.
    2. Briggs, Andrew & Sculpher, Mark & Claxton, Karl, 2006. "Decision Modelling for Health Economic Evaluation," OUP Catalogue, Oxford University Press, number 9780198526629.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Xinyuan Li & Lijun Zhu & Yingying Su & Shaokuan Fang, 2017. "Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-14, October.
    2. Xinyuan Li & Lijun Zhu & Chunkui Zhou & Jing Liu & Heqian Du & Chenglin Wang & Shaokuan Fang, 2018. "Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis," PLOS ONE, Public Library of Science, vol. 13(3), pages 1-15, March.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. David McDaid & A-La Park, 2021. "Modelling the Economic Impact of Reducing Loneliness in Community Dwelling Older People in England," IJERPH, MDPI, vol. 18(4), pages 1-16, February.
    2. Leyla Mohseninejad & Talitha Feenstra & Henriëtte Horst & Hèlen Woutersen-Koch & Erik Buskens, 2013. "Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 947-957, December.
    3. Nicholas Graves & Adrian G Barnett & Kate A Halton & Jacob L Veerman & Elisabeth Winkler & Neville Owen & Marina M Reeves & Alison Marshall & Elizabeth Eakin, 2009. "Cost-Effectiveness of a Telephone-Delivered Intervention for Physical Activity and Diet," PLOS ONE, Public Library of Science, vol. 4(9), pages 1-8, September.
    4. Colin Green & David A Richards & Jacqueline J Hill & Linda Gask & Karina Lovell & Carolyn Chew-Graham & Peter Bower & John Cape & Stephen Pilling & Ricardo Araya & David Kessler & J Martin Bland & Sim, 2014. "Cost-Effectiveness of Collaborative Care for Depression in UK Primary Care: Economic Evaluation of a Randomised Controlled Trial (CADET)," PLOS ONE, Public Library of Science, vol. 9(8), pages 1-12, August.
    5. McDaid, David & Park, A-La, 2021. "Modelling the economic impact of reducing loneliness in community dwelling older people in England," LSE Research Online Documents on Economics 108594, London School of Economics and Political Science, LSE Library.
    6. Chiranjeev Sanyal & Don Husereau, 2020. "Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 375-392, June.
    7. Samer A. Kharroubi & Yara Beyh & Marwa Diab El Harake & Dalia Dawoud & Donna Rowen & John Brazier, 2020. "Examining the Feasibility and Acceptability of Valuing the Arabic Version of SF-6D in a Lebanese Population," IJERPH, MDPI, vol. 17(3), pages 1-15, February.
    8. Nick Bansback & Huiying Sun & Daphne P. Guh & Xin Li & Bohdan Nosyk & Susan Griffin & Paul G. Barnett & Aslam H. Anis, 2008. "Impact of the recall period on measuring health utilities for acute events," Health Economics, John Wiley & Sons, Ltd., vol. 17(12), pages 1413-1419.
    9. Arantzazu Arrospide & Oliver Ibarrondo & Iván Castilla & Igor Larrañaga & Javier Mar, 2022. "Development and Validation of a Discrete Event Simulation Model to Evaluate the Cardiovascular Impact of Population Policies for Obesity," Medical Decision Making, , vol. 42(2), pages 241-254, February.
    10. Clarke, Philip & Erreygers, Guido, 2020. "Defining and measuring health poverty," Social Science & Medicine, Elsevier, vol. 244(C).
    11. Mark Oppe & Daniela Ortín-Sulbarán & Carlos Vila Silván & Anabel Estévez-Carrillo & Juan M. Ramos-Goñi, 2021. "Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 711-721, July.
    12. Kaitlyn Hastings & Clara Marquina & Jedidiah Morton & Dina Abushanab & Danielle Berkovic & Stella Talic & Ella Zomer & Danny Liew & Zanfina Ademi, 2022. "Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia," PharmacoEconomics, Springer, vol. 40(4), pages 449-460, April.
    13. Francesca Cornaglia & Naomi E. Feldman & Andrew Leigh, 2014. "Crime and Mental Well-Being," Journal of Human Resources, University of Wisconsin Press, vol. 49(1), pages 110-140.
    14. Andrea Marcellusi & Raffaella Viti & Loreta A. Kondili & Stefano Rosato & Stefano Vella & Francesco Saverio Mennini, 2019. "Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data," PharmacoEconomics, Springer, vol. 37(2), pages 255-266, February.
    15. Ratcliffe, Julie & Huynh, Elisabeth & Chen, Gang & Stevens, Katherine & Swait, Joffre & Brazier, John & Sawyer, Michael & Roberts, Rachel & Flynn, Terry, 2016. "Valuing the Child Health Utility 9D: Using profile case best worst scaling methods to develop a new adolescent specific scoring algorithm," Social Science & Medicine, Elsevier, vol. 157(C), pages 48-59.
    16. Risha Gidwani & Louise B. Russell, 2020. "Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers," PharmacoEconomics, Springer, vol. 38(11), pages 1153-1164, November.
    17. Stavros Petrou & Oliver Rivero-Arias & Helen Dakin & Louise Longworth & Mark Oppe & Robert Froud & Alastair Gray, 2015. "Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement," Medical Decision Making, , vol. 35(6), pages 1-8, August.
    18. Round, Jeff, 2012. "Is a QALY still a QALY at the end of life?," Journal of Health Economics, Elsevier, vol. 31(3), pages 521-527.
    19. Anirban Basu & William Dale & Arthur Elstein & David Meltzer, 2009. "A linear index for predicting joint health‐states utilities from single health‐states utilities," Health Economics, John Wiley & Sons, Ltd., vol. 18(4), pages 403-419, April.
    20. McCabe, Christopher & Brazier, John & Gilks, Peter & Tsuchiya, Aki & Roberts, Jennifer & O'Hagan, Anthony & Stevens, Katherine, 2006. "Using rank data to estimate health state utility models," Journal of Health Economics, Elsevier, vol. 25(3), pages 418-431, May.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:31:y:2013:i:4:p:317-333. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.